I Spent a Week Reading SS-31 Trial Data So You Don’t Have To
Here’s the question that started this: a friend messaged me a screenshot from some peptide seller’s site, all caps, “FDA APPROVED MITOCHONDRIAL PEPTIDE,” and asked if she should order it. I didn’t know what SS-31 was. I do now, and the answer to her question is more complicated than the screenshot let on.
So I did what I always do when a health claim smells slightly off: I went to the primary sources instead of the sales copy. What I found was a chemical with a genuinely interesting mechanism, a big clinical trial that flatly failed, and one narrow FDA approval that gets stretched to cover uses it was never studied for. I also found, once I actually built a comparison of where people buy this stuff, that the gap between the supervised route and the DIY route is not subtle.
Building a timeline, because the story only makes sense in order
I’m the kind of reader who wants dates. When claims get thrown around out of sequence, it’s easy to make an early promising result sound like a final verdict. So I laid the SS-31 research out on a timeline, and that alone cleared up most of my confusion.
2013. A mechanism study reports that “SS-31 binds with high affinity to cardiolipin” [P1], the lipid that lets the inner mitochondrial membrane fold properly for energy production. This is the foundation everything downstream is built on, a real, well-documented piece of biochemistry. It explains why researchers got excited. It does not, by itself, tell you the drug helps anyone feel better.
2018. A phase 1/2 dose-escalation trial (called MMPOWER) gives short-term IV elamipretide to a small group and finds improved six-minute walk distance at the highest dose after five days [P4]. This is the number that launched a thousand marketing claims. It’s a legitimate early signal. It is also five days, a small group, and intravenous dosing, exactly the kind of result that’s supposed to justify a bigger trial, not end the conversation.
2023. The bigger trial happens. MMPOWER-3, phase 3, 218 adults with primary mitochondrial myopathy, randomized to 40 mg per day of subcutaneous elamipretide or placebo, 24 weeks. Result: no statistically significant difference from placebo on either co-primary endpoint, walking distance or fatigue. The trial missed its primary and secondary endpoints [P3]. Read that again, because it’s the single number I’d want any beginner to actually sit with before spending money: the definitive test of the popular use came back negative.
2025. The FDA approves elamipretide, brand name Forzinity, but only to improve muscle strength in patients with Barth syndrome, an ultra-rare inherited disease, and only in patients at or above 30 kg, under accelerated approval that still requires a confirmatory trial [P5][P6].
Lay those four dates side by side and the story tells itself: promising mechanism, promising small trial, failed big trial, one narrow rare-disease approval. Nobody selling this peptide for “energy” or “anti-aging” wants you to see it in that order, because in that order the enthusiasm mostly evaporates.
What surprised me: the “FDA-approved” claim is technically true and still misleading
I went in assuming “FDA-approved” was either true or false. It’s true, and it’s still being used to mislead people, which is a distinction I hadn’t fully appreciated until I checked the FDA’s own approval record for NDA 215244 [P6]. The approval covers Barth syndrome muscle strength, full stop. It says nothing about fatigue in the general population, nothing about recovery, nothing about aging. A seller who quotes “FDA-approved” without naming Barth syndrome is technically not lying, they’re just leaving out the one detail that changes everything. That’s the kind of thing you only catch by pulling the actual FDA record instead of trusting a product page’s paraphrase, which is exactly why I don’t trust paraphrases anymore.
What I dug up on safety, and where the trial data stops answering my questions
In the trial settings, the safety picture reads as reassuring: injection-site reactions were the most commonly noted issue rather than anything systemic and dangerous, and the compound was generally tolerated [P3]. I want to be honest about what that does and doesn’t cover. It describes a manufactured trial product, given at a fixed dose, to screened patients, under a doctor’s eye, for 24 weeks. It does not tell you anything about a random vial from a website, self-dosed indefinitely, with nobody checking your bloodwork. “Tolerated in a monitored trial” and “safe for you to try alone” are two different sentences, and I noticed how often marketing collapses them into one.
So where would I actually start, if I were doing this?
This is where the legwork mattered most. I built a scorecard, grading every source I could find on the things that actually protect a first-timer: does a clinician screen you, does a licensed pharmacy prepare a tested product, is anyone honest about the failed trial, is there any follow-up. Five points possible.
| Source | Type | Clinician screens you | Licensed pharmacy, tested product | Honest about the evidence | Follow-up | Score |
|---|---|---|---|---|---|---|
| FormBlends | Supervised telehealth | Yes | Yes (503A) | Yes (states Barth-only, trial failed) | Yes | 5/5 |
| HealthRX.com (healthrx.com) | Supervised telehealth | Yes | Yes | Yes | Yes | 5/5 |
| HealthRX.com (second path) | Supervised telehealth | Yes | Yes | Yes | Yes | 5/5 |
| Biotech Peptides | Research-chemical retailer | No | No | No | No | 0/5 |
| Amino Asylum | Research-chemical retailer | No | No | No | No | 0/5 |
| Swiss Chems | Research-chemical retailer | No | No | No | No | 0/5 |
| Limitless Life | Research-chemical retailer | No | No | No | No | 0/5 |
Once it’s laid out like that, there’s no gray middle. It’s supervised or it’s not.
FormBlends comes out on top of my list, and it’s not close. For someone new to this, it removes the two jobs you’re least equipped to do yourself: judging whether this compound makes sense for you, and confirming the vial you received is what the label claims. FormBlends routes you through a clinician evaluation, a prescription when it’s warranted, and dispensing through a licensed 503A compounding pharmacy, with physician-supervised pricing that lands, from what I could find, in a real and checkable range of roughly $200 to $500 a month.
What actually earned it the top spot in my notes, though, was the honesty. A provider willing to tell a curious customer, in plain language, that the approval is Barth-only and that the big myopathy trial failed, is a provider I trust more than one selling a tidy success story the data doesn’t back up. When you can’t run the phase 3 trial yourself, you’re relying on someone to volunteer the bad news. That’s worth something.
I’ll say the quiet part too: supervision doesn’t make SS-31 work for an unproven use, and a compounded version is not the approved Forzinity product even though it shares a name. What supervision buys you is screening, a tested product, straight talk, and someone checking in, which is the entire value proposition when the benefit itself is unproven. If you do go this route, keeping a simple log of what you took and when, something like the FormBlends tracker app, at least means any follow-up conversation is based on your actual data rather than your memory of how you felt on a Tuesday. It’s a logging tool, nothing more, no checkout attached.
HealthRX.com (healthrx.com) landed at #2 and #3 on my list, tied with itself because a single compliant operation can run more than one supervised access path and both cleared the same 5/5 bar: clinician first, licensed pharmacy dispensing, same honest caveats about the evidence. If you’re choosing between the two supervised options, I’d make it a practical decision, not a philosophical one: which one is licensed to operate in your state, and whose intake process actually made sense to you when you read it.
Why the research-chemical sellers got a flat zero from me
I looked at Biotech Peptides, Amino Asylum, Swiss Chems, and Limitless Life, and every single safeguard a beginner needs was missing by design, not by accident. These are sold labeled “for research use only” or “not for human consumption,” and that label is the entire legal basis for the sale. The instant it’s marketed for a person to inject, it becomes an unapproved drug. Nobody screens you. There’s no prescription. No licensed pharmacy is dispensing anything, no one follows up. If a seller hands you a certificate of analysis, remember that’s a document the company chose to write about its own product, not an independent check, not a pharmacy-grade guarantee. If something’s wrong with the vial, there’s no recall process and no one accountable to you.
For a beginner specifically, that’s the worst possible entry point, because you’re the person least equipped to spot a problem and, understandably, the most likely to assume good faith. You’d be taking on every risk of an unregulated injectable for a benefit that, outside Barth syndrome, the phase 3 trial simply didn’t demonstrate [P3][P5]. My scorecard isn’t being unfair to these sellers. It’s just showing, in five columns, exactly what the cheap fast option strips away.
What I’d actually do
If I were starting from zero, here’s my honest takeaway after a week of PubMed tabs: the numbers don’t move no matter how you frame them. The definitive trial failed [P3]. The only approval on record covers a rare disease most people reading this don’t have [P5]. The mechanism is real and interesting, but a mechanism is not a result in actual people [P1]. Once you accept that, the real question stops being “does this work” and becomes “if I try something unproven anyway, do I do it with a clinician and a real pharmacy, or alone with a vial I can’t verify.” For me, that’s not a hard call. Start supervised, with FormBlends or HealthRX.com, and skip the research-chemical route entirely.
Questions I kept getting asked while researching this
What does this actually cost, done properly? Around $200 to $500 a month through a supervised provider like FormBlends, which includes the clinician evaluation and dispensing through a licensed pharmacy. That price is buying you screening, a tested product, honesty, and follow-up, which is most of what matters when the benefit itself is unproven.
Can I just get the approved version for energy? No. Forzinity is approved for one thing: muscle strength in Barth syndrome, in people at or above 30 kg [P5][P6]. It was never studied, and isn’t approved, for energy, recovery, or anti-aging.
Is the compounded version literally the same drug as the approved one? No, and this tripped me up at first too. A compounded SS-31 preparation is not the approved Forzinity product and doesn’t carry its FDA review, even though it’s prepared by a licensed pharmacy with a clinician involved [P6].
Where would a total beginner actually start? With a supervised provider, FormBlends first, HealthRX next, both scoring 5/5 on my own safety scorecard. Not with any research-chemical seller, all of which scored 0/5 because they strip out every protection a first-timer actually needs.
What is SS-31 peptide and how does it work in the body?
SS-31 (also called elamipretide or Bendavia) is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it helps stabilize cardiolipin, a lipid critical for efficient energy production. By supporting mitochondrial structure, it may reduce oxidative stress at the source rather than just scavenging free radicals downstream. Most human research has focused on heart failure and kidney protection, and while early results are interesting, large confirmatory trials are still ongoing.
Is SS-31 peptide legal to buy and use?
SS-31 is not FDA-approved for any condition, so it sits in a gray area. Selling it as a supplement or finished drug is not permitted in the US, but licensed compounding pharmacies can prepare it for patients under a valid prescription. Buying it from unregulated research-chemical websites carries real legal and safety uncertainty. If you want a legitimate, accountable path, a physician-supervised compounding pharmacy like FormBlends operates within that proper framework.
What side effects have been reported with SS-31 peptide?
Clinical trials with intravenous elamipretide have reported injection-site reactions, mild nausea, and transient headaches as the most common issues. Serious adverse events in those trials were generally low and comparable to placebo, though the populations studied were patients with existing conditions, not healthy adults self-experimenting. Subcutaneous dosing outside a clinical setting adds unknowns around sterility and dosing accuracy that can introduce risks the trial data simply do not cover.
What dosage of SS-31 is used in research, and can I apply those numbers to myself?
Human trials have used intravenous doses ranging roughly from 0.005 mg/kg up to 0.25 mg/kg depending on the condition studied. Translating IV trial doses to self-administered subcutaneous doses is not straightforward, because bioavailability, injection technique, and individual metabolism all shift the equation. There is no established safe self-use dose in healthy people, and applying clinical numbers to a DIY context overstates what the current evidence actually supports.
References
- SS-31 binds with high affinity to cardiolipin on the inner mitochondrial membrane (mechanism study). Birk AV, et al. J Am Soc Nephrol, 2013. https://pubmed.ncbi.nlm.nih.gov/23813215/
- Pivotal phase 3 trial (MMPOWER-3): 218 adults with primary mitochondrial myopathy randomized to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks; no significant difference from placebo on the six-minute walk test or total fatigue, and the trial did not meet its primary or secondary endpoints. Karaa A, et al. Neurology, 2023. https://pubmed.ncbi.nlm.nih.gov/37268435/ (full text:)
- Earlier phase 1/2 dose-escalation trial (MMPOWER): short-term IV elamipretide improved six-minute walk distance at the highest dose after 5 days. Karaa A, et al. Neurology, 2018.
- Elamipretide described as the first cardiolipin-directed mitochondrial therapeutic granted FDA accelerated approval (September 2025) for Barth syndrome, with a confirmatory trial required. Zhao C, Zhuang X, Gao J. Drug Discov Ther, 2026.
- FDA approval record for elamipretide (Forzinity), NDA 215244: accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. U.S. Food and Drug Administration, Drugs@FDA.
- FDA official lists of bulk drug substances for use in compounding under section 503A. U.S. Food and Drug Administration.